BJH - volume 13, issue 4, june 2022
T. Feys MBA, MSc
OVERVIEW OF BELGIAN REIMBURSEMENT NEWS
(BELG J HEMATOL 2022;13(4):174)
Read moreBJH - volume 13, issue 4, june 2022
J. Blokken PhD, PharmD, T. Feys MBA, MSc
In this section of the Belgian Journal of Hematology (BJH), we aim to provide a snapshot of pivotal studies published in recent issues of the most important international journals focusing on haematology. Importantly, the selection of the studies discussed here is the sole responsibility of the publisher and was not influenced by third parties. Do you miss an important study, or did you read a hidden jewel that deserves to be shared with your colleagues? Please, let us know (
(BELG J HEMATOL 2022;13(4):175–8)
Read moreBJH - volume 13, issue 3, may 2022
T. Feys MBA, MSc
From 1–4 February 2022, more than 2,300 delegates joined and interacted online during the 2022 European Association for Haemophilia and Allied Disorders (EAHAD) Virtual Congress. During these days, EAHAD 2022 was once again the virtual ‘place-to-be’ for the latest in the field of haemophilia and allied disorders.
(BELG J HEMATOL 2022;13(3):133–6)
Read moreBJH - volume 13, issue 3, may 2022
J. Blokken PhD, PharmD, T. Feys MBA, MSc
In this section of the Belgian Journal of Hematology (BJH), we aim to provide a snapshot of pivotal studies published in recent issues of the most important international journals focusing on haematology. Importantly, the selection of the studies discussed here is the sole responsibility of the publisher and was not influenced by third parties. Do you miss an important study, or did you read a hidden jewel that deserves to be shared with your colleagues? Please, let us know (editor@bjh.be) and we will make sure to include it in the journal scan section of the next BJH issue.
(BELG J HEMATOL 2022;13(3):137–40)
Read moreBJH - volume 13, issue 2, march 2022
T. Feys MBA, MSc
OVERVIEW OF BELGIAN REIMBURSEMENT NEWS
(BELG J HEMATOL 2022;13(2):100)
Read moreBJH - volume 13, issue 2, march 2022
J. Blokken PhD, PharmD, T. Feys MBA, MSc
In this section of the BJH, we aim to provide a snapshot of pivotal studies published in recent issues of the most important international journals focusing on haematology. Importantly, the selection of the studies discussed here is the sole responsibility of the publisher and was not influenced by third parties. Do you miss an important study, or did you read a hidden jewel that deserves to be shared with your colleagues? Please, let us know (editor@bjh.be) and we will make sure to include it in the journal scan section of the next BJH issue.
(BELG J HEMATOL 2022;13(2):101–3)
Read moreBJH - 2022, issue SPECIAL, april 2022
A. Enguita PhD, T. Feys MBA, MSc
Myelofibrosis (MF) is a chronic malignancy characterised by marrow fibrosis and myeloproliferation caused by a constitutive activation of the Janus-activated kinase (JAK) transcription signalling pathway. This constitutive activation is usually the result of mutations in the driver genes JAK2, myeloproliferative leukaemia virus (MPL) or calreticulin (CALR).1 The most important clinical manifestation of MF consists of splenomegaly, in addition to hepatomegaly, cytopenia (mainly anaemia), and constitutional symptoms.2 MF significantly decreases the life expectancy of patients with a median survival of less than six years.3 During the 37th general annual meeting of the Belgian Haematology Society, professor Jean-Jacques Kiladjian (Saint Louis Hospital, Paris, France) discussed the contemporary management of this disease.
Read more
Top
